苑東生物(688513.SH)業績快報:2020年淨利升64.03%至1.78億元
格隆匯2月26日丨苑東生物(688513.SH)披露2020年度業績快報,報吿期內,公司實現營業總收入9.22億元,同比下降2.67%;歸屬於母公司所有者的淨利潤1.78億元,同比上升64.03%;歸屬於母公司所有者的扣除非經常性損益的淨利潤1.13億元,同比上升28.53%;2020年末公司總資產25.27億元,較期初增長156.00%,歸屬於母公司的所有者權益20.95億元,較期初增長200.42%。
受疫情及中標全國集中採購產品價格下降等因素影響,公司2020年度營業總收入同比略有下降,但公司積極採取各項有力措施,加快新產品研發進程,不斷完善產品管線佈局,取得鹽酸美金剛緩釋膠囊、格隆溴銨注射液等6個新產品生產批件;加大市場開拓和渠道建設,推動公司核心製劑產品銷量和市場知名度進一步提升,確保公司利潤實現增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.